Product logins

Find logins to all Clarivate products below.


Neuropathic pain can develop after nerve lesions form at any level of the somatosensory nervous system, peripheral or central; the precise mechanisms that generate pain post-nerve injury are not wholly understood. Such complexity makes it difficult for physicians to diagnose and, consequently, determine an effective treatment for each patient. Primary care physicians and neurologists prescribe therapies from several drug classes, including antiepileptic drugs, antidepressants, NSAIDs, dual-acting opioid analgesics, and opioid analgesics, largely in an escalating sequence to provide patients with adequate analgesia, each of whom may respond differently to the therapies. Antiepileptic drugs and antidepressants are the patient-share leaders in treating neuropathic pain; opioid analgesics are reserved for later-line use for severe or unmanageable pain. Recent efforts in the United States have been implemented to curb the overprescription of opioid analgesics and thus reduce the risk of abuse/misuse associated with these therapies, efforts that are not expected to have much impact in the near future on prescribing of this drug class for neuropathic pain patients. The Current Treatment Overview provides insight into how neuropathic pain is treated and managed today, while the detailed, expanded analysis explores how U.S. primary care physicians and neurologists are treating neuropathic pain and the factors behind their treatment decisions.

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…